Carregant...
Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
Heart failure (HF) accounts for a tremendous burden on health care systems and the society. Since the landmark PARADIGM-HF trial, sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitor (ARNI) showed superiority to enalapril in patients with HF with reduced ejection...
Guardat en:
| Publicat a: | Ann Transl Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8039652/ https://ncbi.nlm.nih.gov/pubmed/33850915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-4038 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|